WILMETTE, Ill., Aug. 27, 2024 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that it has received notice from The Nasdaq Stock Market LLC (Nasdaq) that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) as the closing bid price of the Company’s common stock has been $1.00 per share or more for 10 consecutive trading days. The Company now meets the minimum bid price listing standard for continued Nasdaq listing.
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, including MNPR-101-Zr in Phase 1 for imaging advanced cancers, MNPR-101-Lu in Phase 1 and MNPR-101-Ac225 in late preclinical stages for the treatment of advanced cancers, as well as early-stage programs in solid cancers. For more information, visit: www.monopartx.com.
CONTACT:
Monopar Therapeutics Inc.
Investor information
Karthik Radhakrishnan
Chief Financial Officer
[email protected]
Follow Monopar on social media for updates:
Twitter: @MonoparTx LinkedIn: Monopar Therapeutics
